Skip to NavigationSkip to content

Pharmafile - Sales and Marketing News

Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, the organisation has...
Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents on two of the company’s older...
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at high...
Lynparza has been awarded marketing approval by the European Commission, it has emerged, as a monotherapy for the treatment of human epidermal...
The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure medication.
California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to review the...
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma will now be able to access Eisai and MSD’s Lenvima (lenvatinib) as...
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for prostate cancer, it has emerged...
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 million partnership originally...
A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years old are at risk of fragility...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches